Press

Huxley Health Inc. Provides Corporate Update – Appoints Bruce Linton as Chairman

Jan 30 • 5 min read

TORONTO, Jan. 30, 2024 (GLOBE NEWSWIRE) — Huxley Health Inc. (“Huxley” or the “Company”) is pleased to provide you with a comprehensive corporate update, highlighting significant milestones and developments that have shaped Huxley over the past year. Key Highlights: SINTALICA ACQUISITION The Company is pleased to announce that effective September 26th, 2023, it completed a share purchase…

MindBio Therapeutics Corp. Announces Completion of Landmark Phase 2A LSD Microdosing Clinical Trial in Distressive Disorder

Jan 30 • 2 min read

MindBio Therapeutics Corp. announced it is nearing the completion of its Phase 2a clinical trial using MB22001 in patients with Major Depressive Disorder. MindBio reported that dosing is progressing well in its Phase 2a Depression trial using MB22001 (MindBio’s proprietary titratable form of LSD for take-home Microdosing). The final participant in this landmark clinical trial…

Nirvana Life Sciences Inc. Announces Receipt of First North American Production of SOSA, a Patented, WHO Approved, Herbal Treatment for Opiate Addiction

Jan 29 • 3 min read

Vancouver, British Columbia–(Newsfile Corp. – January 29, 2024) – Nirvana Life Sciences Inc. (CSE: NIRV) (Nirvana or the “Company”), a western Canadian-based life sciences company, is pleased to report that it has received its first shipment of “SOSA”, a leading addictions focused herbal treatment. SOSA is a patented, WHO-approved, herbal treatment for opiate addiction that has…

Psyence Biomedical Ltd. Approved to List on Nasdaq following Completion of Business Combination Agreement with Newcourt Acquisition Corp

Jan 26 • 3 min read

Psyence Biomedical Ltd. (“Psyence Biomed”) is excited to announce the completion of its merger (the “Business Combination”) with Newcourt Acquisition Corp (“Newcourt”), a special purpose acquisition company. The Business Combination will list Psyence Biomed, a subsidiary of Psyence Group Inc (CSE:PSYG), a clinical-stage life science biotechnology company pioneering the use of nature-derived psilocybin in mental…

PharmAla granted a Controlled Drugs & Substances Dealer’s License by Health Canada.

Jan 26 • 3 min read

PharmAla Biotech Holdings Inc. (“PharmAla” or the “Company”) (CSE: MDMA) (OTC:MDXXF), a biotechnology company focused on the research, development, and manufacturing of LaNeo™ MDMA and novel derivatives of MDMA (MDXX class molecules), is pleased to announce that it has been granted a Controlled Drugs & Substances Dealer’s License (CDSL) by Health Canada, Canada’s federal health…

Pages: 123456789101112131415161718192021222324252627282930313233343536373839404142434445464748495051525354555657585960616263646566676869707172737475767778798081828384858687888990919293949596979899100101102103104105106107108109110111112113114115116117118119120121122123124125126127128129130131132133134135136137138139140141142143144145146147148149150151152153154155156157158159160161162163164165166167168169170171172173174175176177178179180181182183184185186187188189190191192193194195196197198199200201202203204205206207208209210211212213214215216217218219220221222223224225226227228229230231232233234235236237238239240241242243244245246247248249250251252253254255256257258259260261262263264265266267268269270271272273274275276277278279280281282283284285286287288289290291292293294295296297298299300301302303304305306307308309310311312313314315316317318319320321322323324325326327328329330331332333334335336337338339340341342343344345346347348349350351352353354355356357358359360361362363364365366367368369370371372373374375376377378379380381382383384385386387388389390391392393394395396397398399400401402403404405406407408409410411412413414415416417418419420421422423424425426427428429430431432433434435